DefiniGEN (an investment in the University of Cambridge Enterprise Funds I & II), a leading provider of stem cell life science products and services has joined the European Bank for induced pluripotent stem cells (EBiSC) consortium. The consortium comprises 26 partners, and has been newly-formed with support from the Innovative Medicines Initiative (IMI) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The EBiSC iPS cell bank will act as a central storage and distribution facility for human iPS cells, to be used by researchers across academia and industry in the study of disease and the development of new therapeutics. DefiniGEN’s role will be to validate EBiSC iPS cell lines by generating liver hepatocyte cells for toxicology, disease modelling, and regenerative medicine applications.
Read the full article here.
